Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound
Clinical trial NCT03529253 · UNKNOWN
Trial details
- NCT number
- NCT03529253
- Sponsor
- Kobe University
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-01
- Primary completion
- 2020-09-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.